# Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors—A Single Center Experience in 152 Patients

## TL;DR

This study shows that using haploidentical donors with post-transplant cyclophosphamide improves survival in patients with hematologic malignancies, especially those not in complete remission.

## Contribution

The study demonstrates that haploidentical donors with PTCy are superior to 9/10 mismatched unrelated donors for patients not in complete remission.

## Key findings

- Haploidentical donors with PTCy showed better survival outcomes compared to 9/10 mismatched unrelated donors.
- Patients not in complete remission before transplantation benefited more from haploidentical donors.
- Donor selection significantly impacts outcomes in allogeneic stem cell transplantation.

## Abstract

Allogeneic hematopoietic stem cell transplantation (allo‐SCT) is a key treatment for hematologic malignancies, but donor selection impacts outcomes.

In a cohort of 152 patients undergoing allo‐SCT from 2012 to 2023, haploidentical donors with post‐transplant cyclophosphamide (PTCy) showed superior survival compared to 9/10 mismatched unrelated donors (MMUD). Cox regression analysis revealed that patients not in complete remission (CR) before transplantation particularly benefited from haplo donors, while those with 9/10 MMUD and lacking CR had worse outcomes.

These results highlight the importance of donor selection, suggesting that haplo donors with PTCy may be preferable for patients not in CR, necessitating alternative approaches for others.

The authors have confirmed clinical trial registration is not needed for this submission.